Corvus Pharmaceuticals (CRVS) Assets (2015 - 2026)

Corvus Pharmaceuticals' Assets history runs 12 years deep, the most recent figure standing at $253.2 million for Q1 2026.

• In Q1 2026, Assets rose 325.98% year-over-year to $253.2 million; the TTM figure through Mar 2026 stood at $253.2 million (up 325.98% YoY), while the FY2025 annual figure was $71.1 million, up 3.21% from the prior year.
• Assets was $253.2 million for Q1 2026 at Corvus Pharmaceuticals, up from $71.1 million in the prior quarter.
• In the past five years, Assets ranged from a high of $253.2 million in Q1 2026 to a low of $40.1 million in Q1 2024.
• Historically, Assets has averaged $79.0 million across 5 years, with a median of $68.2 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Assets tumbled 42.54% in 2023, then jumped 325.98% in 2026.
• A 5-year view of Assets shows it stood at $68.2 million in 2022, then plunged by 33.25% to $45.6 million in 2023, then surged by 51.27% to $68.9 million in 2024, then grew by 3.21% to $71.1 million in 2025, then jumped by 256.02% to $253.2 million in 2026.
• The last three Assets figures came in at $253.2 million (Q1 2026), $71.1 million (Q4 2025), and $80.5 million (Q3 2025), per Business Quant data.